Senate confirms Trump health secretary

The Department of Health and Human Services (HHS) has a new boss, Alex Azar, after nearly four months without a permanent leader.

The Senate confirmed Azar, a former pharmaceutical executive, on Wednesday by a 55-43 vote with six Democrats and Independent Sen. Angus KingAngus Stanley KingOn The Money: Economy adds 75K jobs in May | GOP senator warns tariffs will wipe out tax cuts | Trump says 'good chance' of deal with Mexico On The Money: Economy adds 75K jobs in May | GOP senator warns tariffs will wipe out tax cuts | Trump says 'good chance' of deal with Mexico Trump administration appeals ruling that blocked offshore Arctic drilling MORE (Maine) joining all but one Republican to support the nominee.

Sen. Rand PaulRandal (Rand) Howard PaulOvernight Defense: Pompeo blames Iran for oil tanker attacks | House panel approves 3B defense bill | Trump shares designs for red, white and blue Air Force One Senate rejects effort to block Trump's Qatar, Bahrain arms sales Senate rejects effort to block Trump's Qatar, Bahrain arms sales MORE (R-Ky.) was the lone Republican to vote against his confirmation, after having previously expressed concern over Azar's reticence to let drugs be imported from overseas.

Azar replaces Tom PriceThomas (Tom) Edmunds PriceDemocrats constantly overlook conservative solutions to fix our broken health care Democrats constantly overlook conservative solutions to fix our broken health care Overnight Health Care: CEO of largest private health insurer slams 'Medicare for All' plans | Dem bill targets youth tobacco use | CVS fined over fake painkiller prescriptions | Trump, first lady to discuss opioid crisis at summit MORE, who resigned in September after Politico detailed repeated trips he took on private and military jets, costing taxpayers more than $1 million.

ADVERTISEMENT

Democrats have attacked Azar over drug prices — saying the cost of several drugs more than doubled during his time at Eli Lilly — and expressed concern that he would continue what they view as the Trump administration’s attempts to sabotage ObamaCare.

Meanwhile, Republicans cast Azar’s nearly 10 year tenure at Eli Lilly, where he served as president of Lilly USA from 2012 to 2017 years, as an asset because he already knows the ins and outs of such a complex industry.

Azar will take the helm of the massive department at a critical juncture for ObamaCare. It’s unlikely congressional Republicans will return to the difficult task of repealing and replacing President Obama’s signature health-care law, leaving the White House to seek changes on its own through administrative action.

Azar knows the regulatory process well. Under former President George W. Bush, he served HHS as general counsel from 2001 to 2005. He then became deputy secretary for two years under Secretary Mike Leavitt, who asked Azar to oversee the department’s regulatory process.

“He understands the process and he knows the levers and how you make it work and where the potential roadblocks are,” Leavitt told The Hill last year. “I think he would be of particular value given the fact that ... so far a repeal bill has not occurred and they’re going to need to make their imprint on existing laws through replacing the ideology underpinning it.”

Prescription drugs prices are also likely to be discussed under Azar's tenure. Lawmakers have criticized the high costs of prescription drugs, and President TrumpDonald John TrumpTrump defends Stephanopolous interview Trump defends Stephanopolous interview Buttigieg on offers of foreign intel: 'Just call the FBI' MORE has said drug companies were “getting away with murder.” In nomination hearings, Azar said “drug prices are too high.”

But in those hearings, Democrats expressed concerns over Azar’s record as a pharmaceutical executive, and that was, in part, a reason why some senators voted against his confirmation.

“Here’s my view: Mr. Azar’s nomination is a perfect encapsulation of the president’s broken promises on prescription drugs and health care overall,” Sen. Ron WydenRonald (Ron) Lee WydenOn The Money: Pelosi says no debt ceiling hike until deal on spending caps | McConnell pressures White House to strike budget deal | Warren bill would wipe out billions in student debt | Senate passes IRS reform bill On The Money: Pelosi says no debt ceiling hike until deal on spending caps | McConnell pressures White House to strike budget deal | Warren bill would wipe out billions in student debt | Senate passes IRS reform bill Senate passes bipartisan IRS modernization bill MORE (D-Ore.), the top Democrat on the Senate Finance Committee, said in a press release ahead of a procedural vote on Azar’s confirmation.

The panel’s chairman, Sen. Orrin HatchOrrin Grant HatchTrump to award Medal of Freedom to economist Arthur Laffer Trump gambles in push for drug import proposal Biden's role in Anita Hill hearings defended by witness not allowed to testify MORE (R-Utah) has countered that Azar has the right experience to helm HHS, which oversees everything from Medicare and Medicaid to drug approvals and disease control.

“Mr. Azar spent several years as a senior official at HHS, holding key positions overseeing Medicare Part D and Medicare Advantage. He also led HHS’s responses to the anthrax attacks shortly after 9/11, the SARS and monkeypox crises, Hurricane Katrina, and many others,” Hatch said in a press release ahead of the confirmation vote.

“Clearly, Mr. Azar has seen both the good and bad at HHS and knows how to manage them. I don’t think there is anyone here, even on the other side of the aisle, who would contest that.”

The six Democrats who voted for Azar are Sens. Tom CarperThomas (Tom) Richard CarperBipartisan senators propose forcing EPA to set drinking water standard for 'forever chemicals' Bipartisan senators propose forcing EPA to set drinking water standard for 'forever chemicals' Overnight Energy: Prosecutors drop charges over Flint water crisis | US blames Iran for attack on oil tankers | Air Force diverted M for chemical cleanup costs | Criminal cases referred by Interior at near 25-year low MORE (Del.), Christopher CoonsChristopher (Chris) Andrew CoonsSenate Dem to reintroduce bill with new name after 'My Little Pony' confusion Senate Dem to reintroduce bill with new name after 'My Little Pony' confusion Senate Democrat: Trump Mexico tariff threat 'hopefully' a breaking point for GOP MORE (Del.), Joe DonnellyJoseph (Joe) Simon DonnellyConservatives spark threat of bloody GOP primaries Anti-corruption group hits Congress for ignoring K Street, Capitol Hill 'revolving door' K Street giants scoop up coveted ex-lawmakers MORE (Ind.), Heidi HeitkampMary (Heidi) Kathryn HeitkampLobbying World Pro-trade group targets Democratic leadership in push for new NAFTA On The Money: Stocks sink on Trump tariff threat | GOP caught off guard by new trade turmoil | Federal deficit grew 38 percent this fiscal year | Banks avoid taking position in Trump, Dem subpoena fight MORE (N.D.), Doug Jones (Ala.) and Joe ManchinJoseph (Joe) ManchinThe Hill's 12:30 Report — Presented by MAPRx — Trump takes heat for remarks on help from foreign governments The Hill's 12:30 Report — Presented by MAPRx — Trump takes heat for remarks on help from foreign governments The Hill's Morning Report - Trump and House Democrats resume battle MORE (W.Va.).